Roche's $3.1 billion investment layout: another pharmaceutical giant enters the weight loss drug market
网事大话每
发表于 2023-12-5 19:21:19
1273
0
0
Analysts estimate that the global weight loss market will reach a size of up to $100 billion. Swiss pharmaceutical giant Roche recently announced that it has agreed to acquire unlisted American weight loss drug developer Carmot Therapeutics for an initial price of $2.7 billion. This means that it entered the weight loss drug market by acquiring "Fast Track", challenging weight loss drug giants Novo Nordisk and Lilly. Roche stated that according to the trading contract, the transaction is expected to be completed in the first quarter of 2024. If Carmot Therapeutics achieves individual milestones with its drugs, the company's shareholders can receive $400 million.
Multiple giants are intensifying their layout in the weight-loss drug market
After the transaction is completed, Roche will acquire all current clinical and preclinical assets of Carmot Therapeutics, and employees of Carmot Therapeutics will also join Roche's pharmaceutical department. For Roche, this transaction marks the company's return to the GLP-1 field. Previously, in 2018, Roche abandoned the GLP-1 field when its subsidiary sold a patent for an experimental drug to Lilly for a prepayment of $50 million.
It is reported that Carmot Therapeutics is an American biotechnology company in the clinical stage. Last month, Carmot Therapeutics just submitted its prospectus for listing on NASDAQ and is now being acquired by Roche. Public information shows that Carmot Therapeutics is committed to the development of metabolic disease drugs. At present, the company's products include subcutaneous and oral incretin drugs, which help to treat obesity in diabetes and non diabetes patients and multiple preclinical plans.
In the second half of this year, there were frequent acquisition transactions in the weight loss drug market. In July of this year, Lilly acquired the unlisted Versanis for up to $1.93 billion to further expand its weight loss drug product line; Last month, AstraZeneca agreed to purchase exclusive rights to the development and commercialization of oral GLP-1 weight loss products produced by Chinese biotech company Eccogene for up to $2 billion.
Weight loss pills are selling well, and Novo Nordisk's net profit increased by 43% year-on-year in the first half of the year
Novo Nordisk's previously released financial report for the first half of 2023 showed that during the reporting period, its net sales were 107.667 billion Danish kroner, compared to 83.296 billion Danish kroner in the same period last year, a year-on-year increase of 29%; The net profit was 39.242 billion Danish kroner, compared to 27.528 billion Danish kroner in the same period last year, an increase of 43% year-on-year. Novo Nordisk has raised its annual profit and sales expectations. The CEO of the company said in a statement that Novo Nordisk had raised its annual performance forecast based on the strong demand of the market for diabetes and obesity drugs. The company now serves more patients than ever before.
From the perspective of product line, the sales of diabetes and obesity care increased by 36% to DKK 99 billion, of which the sales of diabetes drug GLP-1 increased by 49%, and the sales of obesity care drugs surged by 158% to DKK 18.1 billion.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Monster Charging CEO Cai Guangyuan: Actively exploring the layout of shared charging business overseas
- Invest an additional 1 billion yuan in cash and traffic every month to recruit service providers and influencers for JD Live
- Indian IT giant Infosys expands cooperation with Nvidia
- Hot pot giant's sluggish performance and busy "self rescue": Haidilao bets on new product categories, Xiabu Xiabu seizes old customers
- Suddenly! The US stock market has fallen sharply! The data warning of chip giants flocking together and diving
- Lithography machine giant, urgent statement
- Jia Yueting talks about iPhone 16 launch event: Apple is becoming mediocre, leaving Steve Jobs more and more like a soulless giant! Luo Yonghao: Zero Innovation
- Increase holdings in Dada to 63.2% and continue to increase holdings in JD's instant retail track layout
- Too sudden! Giants apply for bankruptcy protection, with stock prices plummeting by over 70% this year and a maximum debt of 71 billion yuan
- soar! The market value of "Seven sisters" has soared by 7 trillion yuan! AI chip giant gains over 22% this week, surpassing Tesla in market value
-
每经AI快讯,据亿航智能官微消息,公司EH216-S无人驾驶电动垂直起降航空器(eVTOL)获得巴西国家民航局颁发的试验飞行许可证书,并计划在巴西进行测试和试飞。关于EH216-S无人驾驶eVTOL在巴西的认证,中国民航局 ...
- 潇湘才子
- 昨天 08:41
- 支持
- 反对
- 回复
- 收藏
-
今年7月,美国三大海外“债主”所持美国国债齐刷刷缩水,其中日本美债持仓已降至去年10月以来最低。 根据美国财政部当地时间9月18日公布的国际资本流动报告(TIC),2024年7月,美国前三大海外“债主”日本 ...
- 520hacker
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者俞立严)9月19日,蔚来全新品牌乐道的首款车型——乐道L60正式上市。新车定位家庭智能电动SUV,在采用BaaS电池租用服务后,L60的售价可低至14.99万元,电池租用月费最低为599元。乐道L6 ...
- anhao007
- 前天 11:03
- 支持
- 反对
- 回复
- 收藏
-
每经记者袁园 日前,国务院印发的《关于加强监管防范风险推动保险业高质量发展的若干意见》提出,以新能源汽车商业保险为重点,深化车险综合改革。 “车险综改”从2015年就已经开始逐步推进了,经过 ...
- moshulong
- 前天 21:50
- 支持
- 反对
- 回复
- 收藏